Focused On-demand Library for Small nuclear ribonucleoprotein Sm D3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P62318

UPID:

SMD3_HUMAN

Alternative names:

snRNP core protein D3

Alternative UPACC:

P62318; B4DJP7; B5BU13; P43331

Background:

Small nuclear ribonucleoprotein Sm D3, also known as snRNP core protein D3, is a pivotal component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs). These snRNPs are essential building blocks of the spliceosome, a complex responsible for pre-mRNA splicing, crucial for proper gene expression. This protein is involved in both the pre-catalytic spliceosome B complex and activated spliceosome C complexes, playing a significant role in the splicing of U12-type introns and in histone pre-mRNA 3'-end processing.

Therapeutic significance:

Understanding the role of Small nuclear ribonucleoprotein Sm D3 could open doors to potential therapeutic strategies.